A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

Tejal Patel, Joe Edward Ensor, Jr., Sarah L. Creamer, Toniva Boone, Angel A. Rodriguez, Polly A. Niravath, Jorge Darcourt, Jane L. Meisel, Xiaoxian Li, Jing Zhao, John G. Kuhn, Roberto R. Rosato, Wei Qian, Anna Belcheva, Mary R. Schwartz, Virginia G. Kaklamani, Jenny C. Chang

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)'. Together they form a unique fingerprint.

Medicine & Life Sciences